Myriad Genetics Buys Genetic Marker Technology
Salt Lake City-based Myriad Genetics said this week that it has signed an agreement to acquire proprietary technology from California-based Melanoma Diagnostics, used for the diagnosis and prognosis of malignant melanoma. Financial details of the deal were not announced. Myriad said Melanoma Diagnostics develops technology which uses genetic markers for testing and early detection of melanoma. The deal includes upfront fees and contingent payments for the technology.
posted on Thursday, December 9, 2010
Related companies:
Myriad Capital
Related stories:
> Myriad Genetics Buys Counsyl For $375M
> Myriad Genetics Buys Sividon Diagnostics
> Myriad Genetics At Center Of Supreme Court's Genetics Patent Debate
> Myriad Sponsors Clinical Trial
> Myriad Completes Phase 3 Trial Enrollment
Techrockies.com Home